MX352950B - Metodo para tratar condiciones neurologicas con glicosidos cardiacos. - Google Patents

Metodo para tratar condiciones neurologicas con glicosidos cardiacos.

Info

Publication number
MX352950B
MX352950B MX2014006702A MX2014006702A MX352950B MX 352950 B MX352950 B MX 352950B MX 2014006702 A MX2014006702 A MX 2014006702A MX 2014006702 A MX2014006702 A MX 2014006702A MX 352950 B MX352950 B MX 352950B
Authority
MX
Mexico
Prior art keywords
treating neurological
neurological conditions
cardiac glycosides
cardiac glycoside
disease
Prior art date
Application number
MX2014006702A
Other languages
English (en)
Inventor
Otis C Addington
Robert A Newman
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of MX352950B publication Critical patent/MX352950B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se proporciona un método para tratar una condición neurológica en un sujeto por medio de la administración de un glicósido cardíaco. La enfermedad de Alzheimer, la enfermedad de Huntington o la apoplejía son tratadas al administrar una cantidad terapéuticamente efectiva de un glicósido cardíaco a un sujeto. El glicósido cardíaco puede estar presente en una forma de dosificación.
MX2014006702A 2010-01-11 2012-07-09 Metodo para tratar condiciones neurologicas con glicosidos cardiacos. MX352950B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29381210P 2010-01-11 2010-01-11

Publications (1)

Publication Number Publication Date
MX352950B true MX352950B (es) 2017-12-15

Family

ID=44258983

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012007977A MX2012007977A (es) 2010-01-11 2011-01-10 Metodo para tratar condiciones neurologicas con glicocidos cardiacos.
MX2014006702A MX352950B (es) 2010-01-11 2012-07-09 Metodo para tratar condiciones neurologicas con glicosidos cardiacos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012007977A MX2012007977A (es) 2010-01-11 2011-01-10 Metodo para tratar condiciones neurologicas con glicocidos cardiacos.

Country Status (12)

Country Link
US (4) US8481086B2 (es)
EP (1) EP2523563B1 (es)
JP (1) JP5917413B2 (es)
KR (2) KR101774181B1 (es)
CN (1) CN102834010B (es)
AU (4) AU2011203933B2 (es)
BR (1) BR112012017073A2 (es)
CA (1) CA2786123C (es)
ES (1) ES2638070T3 (es)
MX (2) MX2012007977A (es)
RU (2) RU2582223C2 (es)
WO (1) WO2011085307A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
MX2012007977A (es) 2010-01-11 2012-08-23 Phoenix Biotechnology Inc Metodo para tratar condiciones neurologicas con glicocidos cardiacos.
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
MX345675B (es) * 2010-11-22 2017-02-10 Phoenix Biotechnology Inc Metodo para tratar condiciones neurologicas con extracto de especie nerium o especie thevetia.
CN104721195B (zh) * 2013-12-20 2018-04-27 张震东 华蟾素在制备治疗糖尿病胰岛素抵抗的药物中的用途
US9962485B2 (en) * 2013-12-30 2018-05-08 Cerner Innovation, Inc. Automatically disassociating medical devices from patients
WO2018053123A1 (en) * 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
GB201708456D0 (en) * 2017-05-26 2017-07-12 Medical Res Council Senolytic compounds
CN111417384A (zh) * 2017-09-14 2020-07-14 菲尼克斯生物技术公司 用于治疗神经系统病况的方法和改进的神经保护性组合物
IL285232B (en) 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Preparations containing oleandrin for the treatment of viral infection
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
CN111556761A (zh) 2017-11-15 2020-08-18 拉瓦尔大学 Srsf3药剂用于治疗和/或预防神经病症、癌症、细菌感染或病毒感染的用途
MX2021014579A (es) * 2019-05-29 2022-01-11 Phoenix Biotechnology Inc Metodo y composiciones para tratar una infeccion por el virus linfotropico humano de celulas t tipo 1.
CN111603473B (zh) * 2019-09-30 2022-11-25 上海和黄药业有限公司 一种对神经细胞损伤具有保护作用的组合物及其制剂和用途
KR20220151038A (ko) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 예방를 위한 조성물
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR20230016196A (ko) * 2020-05-24 2023-02-01 피닉스 바이오테크놀러지 인코포레이티드. 올레안드린을 함유한 추출물 및 이의 제조 방법
WO2022187966A1 (en) * 2021-03-10 2022-09-15 Schmitt Ulms Gerold Compounds for altering levels of one or more nka alpha subunits and their use in treating prion diseases or brain diseases associated with cellular prion protein
CN114404425A (zh) * 2022-01-27 2022-04-29 南京中医药大学 一种磷酸二酯酶的抑制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
CA2487732C (en) 2002-05-28 2013-10-15 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
YU102104A (sh) 2002-05-28 2006-05-25 Ortho-Tain Inc. Dentalni aparati i sistemi i metode za distribuiranje dentalnih aparata
US20060135443A1 (en) * 2004-10-18 2006-06-22 Bionaut Pharmaceuticals, Inc. Use of Na*/K*-ATPase inhibitors and antagonists thereof
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
EP1928470A4 (en) 2005-08-02 2010-09-15 Bionaut Pharmaceuticals Inc HYPOXIC INDUCIBLE FACTOR-1 MODULATORS AND RELEVANT APPLICATIONS FOR THE TREATMENT OF EYE DISEASES
JP4428481B2 (ja) * 2006-01-16 2010-03-10 独立行政法人科学技術振興機構 神経因性疼痛治療剤
BRPI0820564A2 (pt) 2007-11-13 2017-05-23 Phoenix Biotechnology Inc método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco
ES2326065B1 (es) 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
AU2009241221B2 (en) * 2008-04-29 2015-02-05 Gunvant Devichand Oswal A homeopathic formulation
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
MX2012007977A (es) 2010-01-11 2012-08-23 Phoenix Biotechnology Inc Metodo para tratar condiciones neurologicas con glicocidos cardiacos.
TWI495307B (zh) 2013-03-14 2015-08-01 Realtek Semiconductor Corp 訊號準位決定裝置及方法

Also Published As

Publication number Publication date
AU2011203933B2 (en) 2016-01-21
AU2016262784B2 (en) 2017-11-23
RU2016109107A3 (es) 2018-11-26
RU2012134341A (ru) 2014-02-20
CN102834010B (zh) 2014-11-05
US9358293B2 (en) 2016-06-07
JP5917413B2 (ja) 2016-05-11
CA2786123A1 (en) 2011-07-14
US20110172172A1 (en) 2011-07-14
US9877979B2 (en) 2018-01-30
KR101774181B1 (ko) 2017-09-01
JP2013516491A (ja) 2013-05-13
US20130302449A1 (en) 2013-11-14
WO2011085307A1 (en) 2011-07-14
EP2523563A4 (en) 2013-08-07
KR20160019973A (ko) 2016-02-22
BR112012017073A2 (pt) 2015-09-01
RU2016109107A (ru) 2018-11-26
US20160243143A1 (en) 2016-08-25
AU2016202421B2 (en) 2016-09-15
KR20130004252A (ko) 2013-01-09
RU2674679C2 (ru) 2018-12-12
ES2638070T3 (es) 2017-10-18
US8481086B2 (en) 2013-07-09
AU2016200181B2 (en) 2016-12-15
EP2523563A1 (en) 2012-11-21
MX2012007977A (es) 2012-08-23
AU2016262784A1 (en) 2016-12-15
RU2582223C2 (ru) 2016-04-20
CN102834010A (zh) 2012-12-19
CA2786123C (en) 2017-11-21
KR101811462B1 (ko) 2018-01-25
AU2011203933A1 (en) 2012-08-23
EP2523563B1 (en) 2017-06-21
AU2016200181A1 (en) 2016-02-04
US20130267475A1 (en) 2013-10-10
US9220778B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX345675B (es) Metodo para tratar condiciones neurologicas con extracto de especie nerium o especie thevetia.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MX2014013858A (es) Metodo para tratar un cancer positivo de gd2.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
NZ715595A (en) Treatment of disease with poly-n-acetyglucosamine nanofibers
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
NZ629964A (en) Method for treating inflammation
EP2596787A4 (en) NEW USE OF HESPERETIN
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
TW201129361A (en) Methods for treating pain
IN2014MN01806A (es)
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
WO2013169291A3 (en) Method for inducing udp-glucuronosyltransferase activity using pterostilbene
CN103301159A (zh) 一种治疗面神经麻痹的中药羚羊全蝎散